Yes, and the models from Triangle assume that chemo use declines by 25% and that the combo is used in about 30% of those cases. (30% of 75% is 22.5%)
So the Triangle model calculates volumes based on 22.5% when the raw response from this medical oncologist was 180%, another oncologist said 115% (slide 27), two more on slides 26 and 27 said 100%.
It would also increase the Maximum Lifetime Cumulative Dose and put upward pressure on chemo usage.
It would seem that 22.5% is very conservative when the raw feedback suggests 100%+ could be observed. Let's leave about half (55%) the value on the table and double the 22.5% to 45% and double their revenue estimate to ... $10Bn to $16Bn per annum.
This is just the cardio protect anti-cancer synergy with chemo drugs, an established market with over 15 million prescriptions per year in the countries shown on slide 16 (which isn't all of them).
- Forums
- ASX - By Stock
- RAC
- Ann: Race releases complete cardio-protection data & video
Ann: Race releases complete cardio-protection data & video, page-61
-
- There are more pages in this discussion • 176 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.92 |
Change
-0.025(1.29%) |
Mkt cap ! $331.3M |
Open | High | Low | Value | Volume |
$1.93 | $1.96 | $1.90 | $154.7K | 80.30K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 900 | $1.92 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.94 | 529 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 900 | 1.915 |
2 | 12508 | 1.910 |
1 | 900 | 1.905 |
1 | 1239 | 1.900 |
2 | 5210 | 1.885 |
Price($) | Vol. | No. |
---|---|---|
1.935 | 529 | 2 |
1.940 | 4063 | 2 |
1.945 | 770 | 1 |
1.950 | 2564 | 1 |
1.975 | 2000 | 1 |
Last trade - 11.04am 16/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online